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Control of immunologic tolerance and homeostasis rely on Foxp31CD41CD251 regulatory T cells (Tregs)
that constitutively express the high affinity receptor for Interleukin-2, CD25. Tregs proliferate in response
to injections of IL-2/anti-IL-2 antibody complexes or low doses of IL-2. However, little is known about
endogenous mechanisms that regulate the sensitivity of CD25 to signaling by IL-2. Here we demonstrate
that CD25 is ADP-ribosylated at Arg35 in the IL-2 binding site by ecto-ADP-ribosyltransferase ARTC2.2, a
toxin-related GPI-anchored ecto-enzyme. ADP-ribosylation inhibits binding of IL-2 by CD25, IL-2-
induced phosphorylation of STAT5, and IL-2-dependent cell proliferation. Our study elucidates an
as-yet-unrecognizedmechanism to tune IL-2 signaling. This newly foundmechanismmight thwart Tregs at
sites of inflammation and thereby permit a more potent response of activated effector T cells.
I
nterleukin 2 (IL-2) activates multiple immune cells, but mounting evidence indicates that its primary function
is to support the generation and survival of Tregs that inhibit immune responses and prevent autoimmune
diseases1–4. IL-2 signals through high and low affinity cell surface receptors5–7. CD25, the a-chain of the IL-2
receptor, is constitutively associated with lipid rafts8. Assembly of the heterotrimeric high affinity receptor
complex is initiated by binding of IL-2 to CD25, followed by recruitment of CD122 and CD132. In the absence
of CD25, theb and c chains form a receptor with a 10–100 fold lower affinity for IL-29. This low affinity receptor is
expressed by naı¨ve T cells, memory CD81 T cells, and NK cells. Both receptors signal via phosphorylation of
STAT5 (signal transducer and activator of transcription 5)10–12. The crystal structure of IL-2 in complex with its
receptor revealed the residues of CD25 involved in binding of IL-26,7, including a prominent arginine doublet
(R35R36) (Supplementary Fig. 1a, b).
T cell subsets are differentially modulated by IL-2 signaling, depending on the concentration of IL-2 and on the
expression of the IL-2 receptor subunits. CD25 is constitutively expressed at high levels by Tregs and IL-2
signaling through CD25 is crucial for the generation, survival and function of these cells1–3,13–15. By efficient
consumption of IL-2, Tregs can deprive neighboring T cells of this cytokine16,17. Recent studies show that in vivo
treatment with low doses of IL-2 or with IL-2 in complex with anti-IL-2 antibodies can suppress immune-
mediated diseases by inducing the expansion of Tregs17–22. IL-2-specific antibodies can prolong the serum
half-life of IL-2 by inhibiting renal filtration of the low molecular weight cytokine23. Intriguingly, different IL-
2/anti-IL-2 antibody complexes induce distinct responses in vivo, depending on the epitope of IL-2 bound by the
particular antibody: mouse IL-2 in complex with mAb (monoclonal antibody) JES6-1A12 or human IL-2 in
complex with mAb 5344 induce the preferential expansion of Tregs, whereas mouse IL-2 in complex with mAb
S4B6 or human IL-2 in complex with mAb-602 induce the preferential expansion of CD81 cytotoxic T cells and
NK cells23–28. These findings raise the question whether endogenous mechanisms exist that could similarly
modulate IL-2 signaling in vivo.
NAD1-dependent ADP-ribosylation is one of the posttranslational modifications regulating protein functions29,30.
NAD1 (nicotinamide adenine dinucleotide) is released from cells during inflammation and acts as a signaling
molecule that alerts immune cells to sites of tissue damage31–34. The NAD1-dependent toxin-related ADP-
ribosyltransferase ARTC2.2 is a GPI-anchored enzyme expressed on the cell membrane of naı¨ve T cells and
Foxp31CD41CD251 regulatory T cells (Tregs)35–37. ARTC2.2 transfers the ADP-ribose moiety fromNAD1 to arginine
residues of other raft-associated membrane proteins35,38. For example, ADP-ribosylation of the P2X7 ion channel at
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R125 induces gating of the ion channel38. ADP-ribosylation of
cell surface proteins can be monitored by autoradiography or by
antibody-based immunoassays (Supplementary Fig. 1c, d).
Here we uncover ADP-ribosylation of CD25 as a novel mech-
anism that controls IL-2 signaling following exposure of Tregs to
extracellular NAD1. Using affinity purification of ADP-ribosylated
cell surface proteins and mass spectrometry, we identify CD25 as a
major target of ARTC2.2.We show that ARTC2.2-catalyzed, NAD1-
dependent ADP-ribosylation of CD25 inhibits IL-2 binding, IL-
2-induced phosphorylation of STAT5, and IL-2-dependent cell-
proliferation. We propose that ADP-ribosylation of CD25 provides
an endogenous mechanism to tune IL-2 signaling in response to
NAD1 released from injured cells during inflammation and tissue
damage. By inhibiting formation of the high affinity IL-2 receptor
naturally expressed by regulatory T cells, thismechanism could allow
the preferential expansion of activated effector T cells in inflammat-
ory settings.
Results
Identification of CD25 as a major target of ARTC2.2. The YAC-1
lymphoma cell line constitutively expresses ARTC2.2 and CD25
(Fig. 1a). Incubation of these cells with 32P-NAD1 resulted in the
labeling of several bands, including a prominent band of 50 kD
(Fig. 1b, lane 1, arrowhead). Similar results were obtained when
etheno-NAD1 was used as substrate (Fig. 1d, lane 1, arrowhead).
Affinity purification of etheno-ADP-ribosylated proteins from
YAC-1 cell lysates (Fig. 1c, d) followed by mass spectrometry
analyses (Fig. 1e) identified the protein in this band as CD25.
Immunoprecipitation analyses with CD25-specific antibodies
verified the identity of the protein in this prominent 50 kD band
as CD25, i.e. this band was depleted from cell lysates and was
recovered in the immunoprecipitate (Fig. 1b, compare lanes 1, 2,
and 4).
ARTC2.2 ADP-ribosylates CD25 at R35 in the IL-2 binding site.
The 3D-structure of human IL-2 in complex with its heterotrimeric
receptor reveals that all eight arginine residues in the visible portion
of the extracellular domain of CD25 are localized on the surface of
the protein and thus are potentially accessible for ADP-ribosylation
(Supplementary Fig. 1b, Fig. 2a). In order to test which of these
arginines could be ADP-ribosylated by ARTC2.2, we individually
substituted each of the arginine residues with lysine by site-
directed mutagenesis. In addition, we purchased a synthetic cDNA
construct of CD25, in which all 11 arginines were substituted by
lysine (RallK). In this construct, we individually substituted each
lysine with arginine, thereby generating variants of CD25 carrying
only a single arginine residue. Each mutant was co-transfected into
HEK (human embryonic kidney) cells together with ARTC2.2. 40 h
post transfection, cell surface expression levels were assessed by flow
cytometry using ARTC2.2 and CD25-specific mAbs (Supplementary
Fig. 2). Parallel aliquots of cells were incubated with 32P-labeled
NAD1. Radiolabeling of CD25 and other cell surface proteins was
assessed by SDS-PAGE autoradiography (Fig. 2b, c).
The results revealed that each of the single R.Kmutants of CD25
still served as a target for ARTC2.2, suggesting that CD25 is ADP-
ribosylated at more than one site (Fig. 2b). Similar results were
obtained for mouse CD25 (Supplementary Fig. 3). This is remin-
iscent of previous reports on the ADP-ribosylation of P2X7 and of
defensin 1, both of which are ADP-ribosylated at more than one
arginine38,39. RallK, the mutant in which all arginines were replaced
by lysine, did not incorporate any radiolabel (Fig. 2c, lane 1) despite
robust expression on the cell surface (Supplementary Fig. 2). This
finding confirms that ADP-ribosylation of CD25 by ARTC2.2 is
arginine-specific. Four of the RallK reversion mutants carrying a
single arginine residue were radiolabeled by ARTC2.2, indicating
that these sites can, in principle, serve as ADP-ribosylation sites for
ARTC2.2 (Fig. 2c, R32, R35, R67, R140). Three of these residues
(R32, R35, R140) are conserved in mouse CD25 (Supplementary
Fig. 4). The fourth residue (R67) is located in a linker between the
two sushi domains that is not visible in the 3D structure. The stronger
labeling of the R67 revertant indicates that this residue is more
accessible for ARTC2.2 than the other revertants. R35 is part of an
arginine doublet (R35/R36), as are the primary ADP-ribosylation
sites on P2X7 and defensin 138,39. R35 is located within the IL-2
binding interface (Supplementary Fig. 1), R32 and R140 are located
on the edges of the first and second Sushi domains, respectively, and
Figure 1 | Immunoprecipitation andmass spectrometry analyses identify
CD25 as a major ADP-ribosylation target on YAC-1 cells. (a) YAC-1 cells
were stained with fluorochrome-conjugated mAbs specific for ARTC2.2
and CD25 and analyzed by flow cytometry. (b) YAC-1 cells were incubated
with 32P-NAD1. Cell lysates were subjected to immunoprecipitation,
proteins were size fractionated by SDS-PAGE, and incorporated
radioactivity was detected by autoradiography. Lanes 1, 2: cell lysates
before and after precipitation of CD25; lane 3: control precipitation with
protein G, lane 4: precipitation with anti-CD25 (PC61). (c–e) YAC-1 cells
were incubated with etheno-NAD1. Etheno-ADP-ribosylated proteins
were purified from the cell lysate using an affinity column with etheno-
adenosine specific mAb 1G4. Bound proteins were eluted in four fractions
with etheno-adenosine. Proteins in the cell lysate (lane 1), column flow
through (lane 2), wash (lane 3), and eluates (lanes 4–7) were size
fractionated by SDS-PAGE. Total protein was visualized by Coomassie
staining (c), etheno-ADP-ribosylated proteins were visualized in a parallel
immunoblot analysis with mAb 1G4 (d). The 50 kD band in lane 5 (panel
c) was excised from the gel and subjected to trypsin digestion and
nanospray mass spectrometry. MALDI-TOF spectrum of a fragmented
tryptic peptide of 1892,9 kD (e). Boxed numbers indicate the masses of
individual peptide peaks, numbers above brackets indicate the mass
differences between adjacent peptide peaks. The amino acid sequence of
the N-terminal peptide of CD25 is shown on top with numbers
corresponding to the masses of the respective peptide fragments. Results
are representative of three independent experiments.
www.nature.com/scientificreports
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R67 is located on the flexible linker between the two sushi domains
that is not visible in the 3D-structure of the IL-2 receptor complex
(Supplementary Fig. 4).
ADP-ribosylation inhibits binding of mAb 7D4 but not mAb
PC61. ADP-ribosylation results in the attachment of a bulky
residue and imparts a local charge change (from a positively
charged arginine to a negatively charged ADP-ribosylarginine)40. It
is, therefore, conceivable that ADP-ribosylation of CD25 at or near
an antibody binding-site could hinder antibody binding. In order to
address this question, we incubatedmouse splenocytes in the absence
or presence of NAD1 followed by staining with the CD25-specific
mAbs PC61 and 7D4 (Fig. 3). The results reveal a NAD1 dose-
dependent inhibition of staining by 7D4 but little if any effect of
NAD1 on the binding of PC61 (Fig. 3b), indicating that ADP-
ribosylation affects the epitope recognized by 7D4 but not the
epitope recognized by PC61.
ADP-ribosylation inhibits IL-2 binding and IL-2-dependent
proliferation of CTLL-2 cells. In order to determine whether
ADP-ribosylation affects binding of IL-2 and IL-2-dependent cell
proliferation, we turned to the IL-2-dependent CTLL-2 cell line
(Fig. 4). In contrast to YAC-1 cells, CTLL-2 cells do not proliferate
in the absence of exogenous IL-2. Moreover, also in contrast to YAC-
1 cells, CTLL-2 cells do not express ARTC2.2 and show little if any
cell surface ART activity (Fig. 4a, panels 2 and 3). Following stable
transfection with ARTC2.2, CTLL-2ARTC2.2 cells acquire the capacity
to ADP-ribosylate cell surface proteins (Fig. 4a, panel 6), with CD25
as a prominent target (Fig. 4b). The availability of ART-negative and
ARTC2.2-expressing CTLL-2 cells permits direct assessment of the
effects of ADP-ribosylation on cellular functions, e.g. by comparing
the responses of CTLL-2ARTC2.2 and parental CTLL-2 cells to
extracellular NAD1.
In order to assess whether ADP-ribosylation of CD25 affects bind-
ing of IL-2, CTLL-2 and CTLL-2ARTC2.2 cells were incubated for
15 min with biotinylated IL-2 in the absence or presence of unlabeled
IL-2 or NAD1. Binding of biotinylated IL-2 was then assessed with
APC-conjugated streptavidin (Fig. 4c). The results show that pre-
incubation with NAD1 inhibits binding of IL-2 by CTLL-2ARTC2.2 cells
but not by parental CTLL-2 cells (grey shaded histograms). In con-
trast, control analyses performed by pre-incubating cells with unla-
beled IL-2 blocked binding of biotinylated IL-2 by both, CTLL-2ARTC2.2
and parental CTLL-2 cells (Fig. 4c, dashed histograms).
In order to assess whether ADP-ribosylation affects IL-2-
dependent cell proliferation, CTLL-2 and CTLL-2ARTC2.2 cells were
depleted of IL-2 by washing with PBS followed by incubation for
6 hours in IL-2 free medium. Cells were then seeded in 24-well plates
in medium containing serial dilutions of IL-2 and cells were culti-
vated further in the absence or presence of NAD1 for 3.5 days. Cell
numbers were assessed by flow cytometry using Trucount beads
(Fig. 4d). The results show that NAD1 does not affect the prolifera-
tion of parental CTLL-2 cells whereas it markedly inhibits the pro-
liferation of CTLL-2ARTC2.2 cells at low and intermediate doses of IL-2
(below 5 ng/ml). These results suggests that ADP-ribosylation of cell
surface proteins interferes with IL-2 binding and with IL-2 signaling.
ADP-ribosylation inhibits IL-2-induced phosphorylation of
STAT5. Binding of IL-2 is known to initiate a signal transduction
pathway resulting in activation of STAT5 by phosphorylation. The
latter can be visualized by flow cytometry with mAb 47 specific for
pSTAT5 (Fig. 5). In order to assess whether ADP-ribosylation
interferes with IL-2-induced phosphorylation of STAT5, CTLL-
2 and CTLL-2ARTC2.2 cells were treated with NAD1 and then
analyzed by FACS for IL-2-induced phosphorylation of STAT5
(Fig. 5a). The results show that treatment with extracellular NAD1
inhibits IL-2-induced phosphorylation of STAT5 in case of CTLL-
2ARTC2.2 cells (Fig. 5a, panel 2, shaded histogram) but not of parental
CTLL-2 cells (Fig. 5a, panel 1). Preventing ARTC2.2-catalyzed ADP-
ribosylation of cell surface proteins with the ARTC2.2-blocking
nanobody s116a41 completely prevented inhibition of STAT5
phosphorylation in CTLL-2ARTC2.2 cells in the presence of NAD1
Figure 2 | Identification of of R32, R35, R67, and R140 as the
ADP-ribosylation sites onCD25. (a) Schematic diagramof the 11 arginine
residues in the extracellular domains of human CD25. Numbers
correspond to the position within the amino acid sequence of the native
protein, i.e. after removal of the signal peptide. Dashed lines indicate
residues not visible in the 3D-structure of the IL-2 receptor complexed
with IL-2 (2erj). TMD: transmembrane domain. (b, c) HEK cells were co-
transfected with expression vectors for ARTC2.2 and either a non-ADP-
ribosylated control antigen (co), wild type CD25 (WT), or CD25 variants.
Analyzed mutants of CD25 include single R. K mutants (B), a synthetic
construct in which all arginine residues in the extracellular domain were
replaced by lysine (RallK), and variants of RallK carrying individual K. R
back mutations (c). 48 hours post transfection, cells were incubated
with 32P-NAD1. Radiolabeled proteins were detected by SDS-PAGE
autoradiography. Results are representative of four independent
experiments. Numbers indicate the relative labeling intensity of individual
bands (mean from four repeats).
Figure 3 | ADP-ribosylation inhibits binding of anti-CD25mAb 7D4 but
not of mAb PC61. Splenocytes from DEREG mice were incubated in the
absence or presence of the indicated concentrations of NAD1 before
staining with fluorochrome-conjugated mAbs directed against CD4 and
CD25 (mAb PC61 or mAb 7D4). Gating was performed on CD41 cells.
(a) Representative dot plots of cells incubated in the absence or presence of
12 mM NAD1. (b) Percentages of CD41GFP1 cells staining with
anti-CD25 mAbs plotted as a function of the concentration of added
NAD1. Results are representative of two independent experiments.
www.nature.com/scientificreports
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(Fig. 5b, panel 2), confirming that the effect of NAD1 on STAT5
phosphorylation is dependent on ARTC2.2 catalyzed ADP-
ribosylation.
Naturally occurring Foxp31 Tregs constitutively express CD25
and ARTC2.237. DEREG-transgenic mice express a diphtheria-toxin
receptor-GFP fusion protein under control of the foxp3 promoter,
allowing visualization of living Tregs by flow cytometry42. The avail-
ability of ARTC22/2 DEREG mice37 permits a direct assessment of the
effect of NAD1-dependent ADP-ribosylation on Tregs, e.g. by com-
paring the responses of Tregs from ARTC22/2 and wildtype DEREG
mice to extracellular NAD1 (Fig. 5c and Supplementary Fig. 5).
Treatment of FACS-sorted Tregs with extracellular NAD1 inhibited
IL-2-induced phosphorylation of STAT5 (Fig. 5c). Similarily, treatment
of unsorted splenocytes with NAD1 inhibited phosphorylation of
STAT5 in wildtype Tregs cells but not in ARTC22/2 Tregs (Sup-
plementary Fig. 5a–c). We have previously shown that ADP-
ribosylation induces gating of the P2X7 ion channel, resulting in
Calcium influx and externalization of phosphatidylserine38. In order
to determine whether the inhibition of IL-2-induced STAT5 phos-
phorylation was mediated by P2X7, we analyzed the effects of extra-
cellular NAD1 also on cells from P2X72/2 (ARTC21/1) DEREG mice
(Supplementary Fig. 5e). The results show that NAD1-treatment inhi-
bits STAT5 phoshporylation also in purified Tregs from P2X72/2
(ARTC21/1 mice), indicating that this effect is independent of P2X7
activation.
Discussion
The results presented here identify CD25, the a chain of the interleukin-
2 receptor, as a major target for ADP-ribosylation by the toxin-
related ecto-enzyme ARTC2.2 (Fig. 1) and provide insight into the
role of ADP-ribosylation of CD25. ADP-ribosylation assays in HEK
cells co-transfected with ARTC2.2 and CD25 mutants identified R35
at the arginine doublet R35R36 as a target site for ADP-ribosylation
(Fig. 2). This is reminiscent of murine P2X7 and human defensin 1,
both of which contain double arginines as primary sites of ADP-
ribosylation, but are additionally ADP-ribosylated on other argi-
nine residues38,39. R35 is localized within the IL-2 binding region
(Supplementary Figs. 1d, 4)7,43. Considering that ADP-ribosylation
results in the attachment of a bulky residue, converting a positively
charged arginine into a negatively charged ADP-ribosylarginine, it
is not surprising that ADP-ribosylation at this residue interferes
with binding of IL-2 (Fig. 4c). Consistently, ADP-ribosylation of
CD25 inhibits IL-2-induced phosphorylation of STAT5 (Fig. 5a, c)
as well as IL-2-dependent cell proliferation (Fig. 4f). Of note, ADP-
ribosylation of CD25 blocks binding of mAb 7D4 (Fig. 3), an
Figure 5 | ADP-ribosylation inhibits IL-2-induced phosphorylation of
STAT5 by CTLL-2ARTC2.2 cells and by ARTC21/1 Tregs. (a) CTLL-2 and
CTLL-2ARTC2.2 cells were pre-incubated in the absence or presence of NAD1
before stimulation with IL-2 for 15 min. Cells were fixed and stained with
fluorochrome-conjugated antibodies against phosphorylated STAT5
(pSTAT5). Control cells were incubated without NAD1 or IL-2. (b) CTLL-
2 and CTLL-2ARTC2.2 cells were pre-incubated with the ARTC2.2-blocking
nanobody s116a (nb) before addition ofNAD1 and stimulationwith IL-2.
(c) Tregs were FACS-sorted from wildtype DEREG mice and incubated in
the absence or presence of NAD1 before stimulation with IL-2 and staining
for pSTAT5. Results are representative of two independent experiments.
Figure 4 | ADP-ribosylation inhibits binding of IL-2 and IL-2-dependent
proliferation of ARTC2.2-transfected CTLL-2 lymphoma cells.
(a) Untransfected parental and ARTC2.2-transfected CTLL-2 cells were
incubated with etheno-NAD1 and stained with fluorochrome-conjugated
mAbs specific for CD25, ARTC2.2, and etheno-adenosine and analyzed by
flow cytometry. (b) CTLL-2ARTC2.2 cells were incubated with 32P-NAD1 and
cell lysates were subjected to immunoprecipitation with anti-CD25 and
SDS-PAGE autoradiography as in Fig. 1b. Lanes 1, 2: lysates before and
after precipitation of CD25, lane 3: control precipitation with protein G,
lane 4: precipitation with anti-CD25. (c) CTLL-2 and CTLL-2ARTC2.2 cells
were pre-incubated in the absence or presence of NAD1 or unlabeled IL-2.
Cells were then incubated with biotinylated IL-2 before addition of
fluorochrome-conjugated streptavidin and analysis by flow cytometry.
(d) CTLL-2 and CTLL-2ARTC2.2 cells were seeded in a 24 well culture plate
(3 3 104/well) and incubated for four days in medium containing the
indicated concentrations of IL-2. Medium lacking or containing NAD1
was added every 12 hours. Cell numbers were assessed by flow cytometry
with the aid of Trucount beads (BD). Results are representative of two
independent experiments.
www.nature.com/scientificreports
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antibody that is commonly used for bead-assisted sorting of Tregs.
Considering that endogenous NAD1 can be released during manip-
ulation of cells37,44, inadvertent ADP-ribosylation of CD25 prior to
staining with 7D4 may hamper bead-assisted sorting of Tregs.
Indeed, NAD1-mediated ADP-ribosylation of CD25 may explain
the reported difficulty to purify Tregs from CD38ko mice using
bead-assisted sorting45 since lack of the major cell surface NAD-
hydrolase in these mice causes exposure of cells to higher levels of
extracellular NAD137,46. We recently described a simple means to
prevent inadvertent ADP-ribosylation of cell surface proteins during
preparation of cells from spleen or liver, i.e. systemic injection of an
ARTC2.2-blocking nanobody ten minutes prior to sacrifice of mice47.
Figure 6 illustrates a model whereby ADP-ribosylation of CD25
provides a regulatory mechanism for tuning IL-2 signaling, i.e. from
CD25-dependent high affinity signaling to CD25-independent low
affinity signaling via CD122/CD132. In a non-inflammatory envir-
onment, where the concentration of extracellular NAD1 is low, con-
sumption of extracellular IL-2 by Tregs would deprive other T cells
and NK cells of IL-2 (Fig. 6a)48. Similarly, systemic injections of low
doses of IL-2 may result in the preferential expansion of
Tregs17,19–21,49. In an inflammatory environment, where stressed
and damaged cells release large amounts of NAD1 into the extra-
cellular compartment44,50, ADP-ribosylation of CD25 would divert
IL-2 signaling away from Tregs to NK cells and CD81 cytotoxic T
cells (Fig. 6b). This mechanism of tuning IL-2 signaling may be
mimicked by certain IL-2 antibodies used in vivo (Fig. 6c), i.e.
systemic injections of mouse IL-2 in complex with mAbs S4B6 or
JES6-5HA or of human IL-2 in complex with Mab-602 cause pref-
erential expansion of NK cells and cytotoxic T cells22,24,27. In addition
to Tregs that constitutively express CD25, CD25 is also up-regulated
by activated T cells following triggering of the TCR (T cell receptor)51
(Supplementary Fig. 6). Since TCR triggering induces metallopro-
tease-mediated shedding of ARTC2.2, activated T cells are rendered
resistant to ADP-ribosylation of cell surface proteins52. Therefore,
ADP-ribosylation of CD25 may be a Treg-specific regulatory mech-
anism. The finding that some Tregs appear unaffected by NAD1
treatment (Fig. 5C, Supplementary Fig. 5) could be due to lower
expression of ARTC2.2 or CD25 or due to differential localization
of these antigens in the plasma membrane, e.g. inside/outside lipid
rafts8,35. Future studies should address potential differences of dis-
tinct subpopulations of Tregs in their sensitivity to NAD1-mediated
regulation of IL-2 signaling.
In summary, we have described here a previously unknownmech-
anism for tuning signaling by IL-2 by ADP-ribosylation of CD25.
Operation of this mechanism in vivo likely depends on the context in
which T cells are exposed to NAD1. Thus, at sites where NAD1 is
released in large quantities from damaged cells, such as during a lytic
viral infection, ADP-ribosylation of CD25 on Tregs would favor
proliferation and function of CD81 effector T cells, thereby enhan-
cing pathogen eradication. In contrast, in healthy tissues, where little
if any NAD1 is released, Treg function would not be inhibited by
ADP-ribosylation, permitting IL-2 mediated expansion of Tregs and
efficient suppression of potentially auto-reactive T cells.
Methods
Mice and cells. ARTC22/2mice53 and P2X72/2mice54 were backcrossed to C57BL/6
WT and DEREG mice42 on the C57BL/6 background for 12 generations and were
maintained under specific pathogen-free conditions at the central animal facility of
the UKE. All experiments were performed according to state guidelines with approval
of the local institutional regulatory committee (registration numbers ORG153 and
A10a). The YAC-1 lymphoma cells, kindly provided by Ju¨rgen Lo¨hler, Heinrich Pette
Institute, Hamburg, Germany, were cultured in RPMI-1640 supplemented with 10%
FCS, 2 mM glutamine, 2 mM sodium pyruvate. The IL-2-dependent CTLL-2 cell-
line, kindly provided by Marc Pallardy, INSERM U 461, Chaˆtenay-Malabry, France,
was maintained in complete medium supplemented with 10 ng/ml human
recombinant IL-2 (10000 U/ml, Roche) and 0.0001% 2-mercaptoethanol. CTLL-2
cells were stably transfected with an expression construct for ARTC2.2 (pME.CD8LF-
ARTC2.2)55. Tregs were FACS-sorted as GFP1 cells from primary spleen cells of
DEREG mice at 4uC. Alternatively, after erythrocyte lysis with Ack lysis buffer (Bio
Whittaker) and depletion of B-cells with Dynabead-conjugated sheep anti-mouse
IgG (Invitrogen), Tregs were positively selected by magnetic cell sorting using PE
conjugated anti-CD25 (7D4) and magnetic bead-conjugated anti-PE antibodies
according to the manufacturer’s instructions (Miltenyi Biotec). Purity of Tregs was
monitored by flow cytometry and was .90%.
Flow cytometry. Fluorochrome-conjugated mAbs were used against mouse CD25
(PC61, 7D4) human CD25 (M-A251), CD4 (GK1.5), ARTC2.2 (Nika102), etheno-
adenosine (1G4), and pSTAT5 (47). Stained cells were analyzed with a FACS Canto II
(BD) and FlowJo software (TriStar).
Site directed mutagenesis and cell transfections. The coding regions for mouse and
human CD25 were PCR-amplified from YAC-1 lymphoma cells and from ConA-
stimulated PBLs, respectively, and cloned into the pCMV-Sport6 vector (Invitrogen).
Arginine residues were substituted with lysine using site-directed mutagenesis. A
synthetic cDNA encoding CD25 in which all arginine residues in the extracellular
domainwere replaced by lysine, was purchased fromGeneart (Invitrogen) and cloned
into pCMV-Sport6. Expression constructs (2 mg per 106 cells) were transfected into
CTLL-2 cells by electroporation and into HEK cells with the jetPEI transfection
reagent (Polyplus).
Purification of etheno-ADP-ribosylated proteins and mass spectrometry. YAC-1
cells (109 cells in 10 ml) were incubated for 15 min at RT with 10 mM etheno-NAD1
(Sigma) and washed twice in PBS before lysis in 1% Triton-X 100 for 20 min at 4uC.
Cell lysates were clarified by high speed centrifugation (20 min 15.000 g) before
passage through a 1 ml affinity column containing mAb 1G4 immobilized on
Amino-Link Matrix (Pierce). The column was extensively washed with 1% Triton
X-100 and PBS, bound proteins were eluted with 1 mM etheno-adenosine in PBS/
0.1% Triton-X-100. Eluted proteins were size fractionated by SDS-PAGE. Proteins
were stained with Coomassie blue and visible bands were cut out. A parallel gel was
blotted onto a PVDF membrane and subjected to Western-Blot analyses with
etheno-adenosine specific mAb 1G4 and peroxidase-conjugated anti-mouse IgG. A
Figure 6 | Model for the tuning of IL-2 signaling by ADP-ribosylation of
CD25. (a) Tregs constitutively express high levels of CD25 while CD81 T
cells and NK cells express only the b and c chains of the IL-2 receptor
(CD132, CD122). In a non-inflammatory environment, Tregs consume
IL-2 due to the higher affinity of CD25 compared to CD122/CD132,
thereby depriving neighboring CD8 cells and NK cells of this cytokine.
(b) In an inflammatory environment, i.e. following the release of NAD1
from damaged cells, ADP-ribosylation of CD25 (blue circles) diverts IL-2
from the high affinity receptor to the low affinity b and c chains, allowing
efficient expansion of CD8 cells andNK cells. (c) Systemic injection of IL-2
in complex with antibodies that prevent binding of IL-2 to CD25 similarly
results in preferential expansion of CD8 cells and NK cells.
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prominent 50 kD band was excised from the gel. Following reduction of disulfide
bonds with DTT (10 mM, 56uC, 30 min) and modification of cysteines with
iodoacetamide (55 mM, RT, 20 min), proteins were subjected to in-gel digestion with
trypsin (5 ng/ml in 50 mMNH4HCO3, 37uC, 16 h). Peptides were extracted with 50%
acetonitrile/5% formic acid, dried in a vacuum concentrater, redisolved in 5%
methanol/5% formic acid desalted on a C18 mZipTip (Millipore), eluted with 1 ml
60% methanol/5% formic acid, and analyzed by nano-electrospray mass
spectrometry in a QTOF II instrument (Micromass). MS/MS spectra obtained by
collision induced fragmentation after manual precurser selection were evaluated both
manually and by the Mascot MS/MS search algorithm version 2.2 (Matrix Sciences,
London, UK).
Radio-ADP-ribosylation assays. HEK cells were transiently co-transfected with
ARTC2.2 (1 mg/106 cells) and CD25 (2 mg/106 cells) in solution and plated in parallel
aliquots onto 6-well plates pre-coated with poly-L-lysine. 48 h post transfection, one
aliquot was used to monitor transfection efficiency by FACS analyses using mAbs
directed against ARTC2.2 and CD25. The adherent cells of the other aliquot were
gently washedwith pre-warmed serum-free X vivomedium (BioWhittaker) and then
incubated in serum free X vivo medium containing 32P-NAD1 (2,5 mCi, 0,4 mM) for
20 min at 37uC. Cells were gently washed with pre-warmed X vivo medium and then
lysed in PBS, 1% Triton-X100, 1 mM AEBSF (Sigma) for 20 min at 4uC. Insoluble
material was pelleted by high-speed centrifugation (15 min 13.000 g) and solubilized
membrane proteins were size fractionated on precast SDS-PAGE gels (Invitrogen)
(13 105 cell equivalents/lane). Proteins were detected by Coomassie staining of the
gels. For detection of radiolabeled proteins, gels were exposed to an X-ray film at
280uC for 6h–6d.
Immunoprecipitation of CD25. The CD25-specific mAb PC61 was conjugated to
amino-link beads according to the manufacturer’s instructions (Pierce). After
incubation with cell lysates for 60 min at 4uC, beads were washed with PBS, 1%
Triton-X 100. Samples were then incubated at 70uC for 15 min and the matrix was
pelleted by centrifugation. Proteins eluted from the matrix were analyzed by
SDS-PAGE autoradiography as described above.
Cell proliferation assay. In order to deplete CTLL-2 cells from IL-2, cells were
washed twice and incubated for 6 h in culture medium without IL-2. Cells were
seeded in a 24-well plate (33 104 cells per well) and cultivated in medium containing
serial dilutions of IL-2. A small aliquot of medium containing or lacking NAD1 (final
concentration 100 mM) was added every 12 hours. Cell numbers were determined
after four days by flow cytometry using TrucountTM beads (BD).
STAT5 phosphorylation assay. Primary splenocytes and purified Tregs (1 3 105
cells/100 ml) were incubated in the absence or presence of 30 mMNAD1 for 15 min at
4uC before addition of 2.5 U/ml mouse IL-2 (eBioscience) and further incubation for
5 min at 37uC. The cells were then fixed in 2% PFA for 10 min at 37uC and 90%
methanol at 220uC before staining with APC-conjugated anti-phospho-STAT5
according to the manufacturer’s instructions (BD). Splenocytes were counterstained
with anti-CD4 before incubation with IL-2. In some experiments, cells were
preincubated for 15 min in the presence of the ARTC2.2-blocking nanobody s116a
(50 ng/ml)41.
Interleukin-2 binding assay. 1 3 105 cells were incubated with 5 ng biotinylated
Interleukin-2 (R&D Systems) or 10 ng biotinylated soybean-trypsin inhibitor in
100 ml PBS, 0.1% BSA for 60 min at 4uC before addition of 100 ng APC-conjugated
streptavidin (BD). Parallel aliquots of cells were pre-incubated with or without
unlabeled mIL-2 (500 ng, eBioscience) or 50 mM NAD1.
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